Monday, September 9, 2019

Gastric Cancer - An Update_Juniper Publishers


Journal of Tumor Medicine & Prevention Juniper Publishers



Authored by Neeraj Nagaich

Introduction

The incidence of gastric cancer is highest in eastern Asia, Eastern Europe, and South America, and it affects twice as many men as women. Risk factors for gastric cancer include Helicobacter pylori infection, cigarette smoking, high alcohol intake, excess dietary salt, lack of refrigeration, inadequate fruit and vegetable consumption, and pernicious anaemia. Patients present with weight loss and abdominal pain, although those with proximal or gastro-esophageal junction tumours may present with dysphagia. Upper gastrointestinal endoscopy with biopsy is used to confirm the diagnosis; precise tumour stage is defined by more sophisticated radiological investigations. Multidisciplinary approach to treatment: early gastric cancer is treated with surgery alone, whereas advanced disease is usually managed with chemotherapy before and after surgery, or postoperative chemo radiation.
With improvements in detection, staging, and treatment, the over- all mortality rate from gastric cancer has similarly decreased. In spite of these gains, the overall prognosis for patients with gastric cancer remains poor, with approximately 30% surviving 5 years past their initial diagnosis. The optimal therapeutic strategy for patients with gastric cancer, particularly those classified as locally advanced, remains undefined. Although surgical resection is the mainstay of treatment for non-metastatic gastric cancers, significant controversy persists over the role of extended lymph adenectomy. Selecting an ideal treatment strategy in the neo-adjuvant or adjuvant setting is perhaps even more challenging. Metastatic disease is managed with chemotherapy or chemo radiation as well as supportive care measures.

Epidemiology and Aetiology

Globally, Gastric Cancer (GC) incidence has been shown to be more common in men and the increase with age, with most case occurring after the age of 60 years. However, GC incidence rates vary dramatically across countries. The geographic distribution of GC has been mainly attributed to difference in dietary patterns, socioeconomic status, and the prevalence of Helicobacter pylori infections. The highest GC incidence and mortality rates occur in Eastern Asia, Central and Eastern Europe, and South America. Mortality rates associated with GC, even in developed countries, are still very high only 28.3% of newly diagnosed cases are expected to survive 5 years of longer after diagnosis.
Stomach cancer is the second-most common cancer among men and third-most among females in Asia and worldwide. The symptoms and sign of stomach cancer are often reported late when the disease is already in advanced stages and 5-year survival is less than 30% in developed countries and around 20% in developing countries. Despite of large number of such patients being treated in, there is lack of sufficient publications on the epidemiology of gastric cancer from India. Most of the reported studies on gastric cancer from India are case reports or case series and few are case-control studies and they often deal with few specific risk factors associated with gastric cancer without looking into the entire spectrum of the disease. Hence there is an urgent need for more research is to understand the etiology, develop suitable screening test, to demarcate high-risk population.
Gastric cancer is the fourth most common cancer in the world and the second leading cause of cancer deaths worldwide with more than 700000 deaths annually [1]. After the discovery of Helicobacter pylori (H. Pylori) in 1983, the casual relationship between this bacterium and gastritis or gastric cancer has been steadily elucidated. In 1994, H. Pylori was classified as a carcinogen by the International Agency for Research on Cancer of the World Health Organization (WHO). A 2009 meta-analysis showed that H. Pylori eradication appeared to reduce the risk of gastric cancer [2]. In Japan, approximately 99% of gastric cancers are caused by H. Pylori; thus, H. Pylori-negative gastric cancer constitutes less than 1% of all cases [3]. There has been a progressing decrease in the incidence of gastric cancer around the world largely due to eradication of Helicobacter pylori and other risk factors that are not completely understood [4].
Across the globe and particularly in Asia, Gastric cancer remains the most common cancer among men and the most common cause of cancer related deaths in countries such as Japan. In Japan and other parts of the Asia, non cardiac tumors continue to be more common compared with the west.

Gastric Cancer Causes and Risk Factor

Infectious Agents Associated with Gastric Cancer:

Helicobacter pylori

In 1994, the international Agency for Research on Cancer classified H pylori, the first formally recognized bacterial carcinogen, as a class I human carcinogen for GC. H Pylori are involved in 90% of all gastric malignancies. H. Pylori incidence varies according to age, ethnicity, and geographic location. In location such as Mexico, Argentian and Asia countries the prevalence of H. Pylori ranges from 30% to 70% by the age of 20 years and 70% to 90% by the age of 60 years. In the US and France, the prevalence is approximately 20% and 40% for younger and older ages, respectively.
H. Pylori contributes to the development of gastric neoplasia by promoting inflammation in the gastric mucosa (gastritis), which leads to sequential histopathology changes that may result in the development of GC. However, not every individual infected with H pylori will develop GC. The exact path physiological mechanisms, as well as the contribution of environmental risk factors and host genetic susceptibility in the progression of gastric carcinogenesis, have yet to be fully elucidated. H pylori virulence factors have been associated with a higher risk of GC. Infection with H pylori strains with vacAC1-, vacAm-1, and cagA - Positive genotypes are associated with an approximate 6-fold increases in GC risk. Increasing evidence supports that the extent of the inflammatory response to H pylori is in large part determined by polymorphisms in host genes encoding cytokines and cytokine receptors individuals with pro inflammatory interleukin genotypes infected with H pylori strains with VacAs-1-, vacAm1-, and cagA-positive genotypes were reported to have up to an 87-fold higher risk of GC compared with H pylori-infected individuals without pro inflammatory IL -1 polymorphisms. Recently, GC stem cells were also proposed as a gastric carcinogenesis mechanism. Chronic infection with H pylori induces recruitment of bone marrow-derived cells that, once recruited, differentiate with local gastric epithelia cells, ultimately inducing stem cell properties and leading to cell metaplasia, dysplasia, and adenocarcinoma. Unfortunately, there are currently no robust biomarkers clinically available to reliably predict who will develop GC cancer after H pylori infection.

Epstein-barr virus

Multiple studies in different parts of the world have found the prevalence of Epstein-Barr virus (EBV) in 5% to 16% of gastric carcinomas, which supports its possible role as an etiologic agent of GC. In Asia, Europe and the America’s prevalence of EBV is close to 9% of all GC cases reported. Male patients have been found to be twice as likely to have EBV-positive tumors compared with females. Tumors in the gastric cardia or corpus were found to be twice as likely to be EBV-positive compared with those in the antrum. Although the role of EBV in gastric carcinogenesis is not yet clearly defined, EBV-positivity has been reported to be associated with favorable prognosis.

Genetic predisposition

Familial gastric cancer: An estimated 20% of GC patients have a family history of GC. According to the racial or ethnic group, family history was shown to confer 2-fold to 10-fold increased risk of GC. Although most GCs are sporadic, 10% of the cases have familial clustering and 1% to 3% are hereditary. Hereditary GC includes syndromes such as hereditary diffuse GC (HDGC), gastric adenocarcinoma and proximal proximal polyposis of the stomach, and familial intestinal GC. HDGC is a rare, autosomal dominant disorder that is responsible for 1% to 3% of all familial GC cases. About 40% of individuals with HDGC have germline mutations in the CDH1 gene, which encodes E-cadherin. In the presence of CDH1 mutations, the lifetime risk of developing GC is 70% to 80%. GC can also develop as part of familial cancer syndromes, including Lynch syndrome, familial adenomatous polyposis, Peutz-Jeghers syndrome, and Li-Fraumeni syndrome. GC is part of the Lynch syndrome tumor spectrum; GC risk is 2.9 times higher subjects with germline MLH1 mutations.

Demographic, environmental and risk factors

In addition to infectious agents and family history, additional GC risk factors include age, gender, certain occupations, tobacco use, diet, and being overweight, among others. The risk of developing GC is twice as high in men as in women and it is usually diagnosed between the ages of 60 to 80 years. Individuals with certain occupations, such as those who work in the coal, metal, and rubber industries, have been reported to have an increased risk of GC. Tobacco smoking has been reported to cause a 60% and 20% increase in GC risk in men and women, respectively. It is estimated that 18% of GC cases are attributable to tobacco smoking. No association has been found between smokeless tobacco and GC. In contrast, alcohol consumption has not been consistently shown to be associated with GC; however, it has been identified as a risk factor for disease progression. A 5-fold increased risk of GC has been observed as a result of the combined effect of alcohol and smoking. A high intake of salted, pickled or smoked foods, and preserved foods rich in salt and nitrites have been reported to be associated with an increased risk of GC, whereas foods rich in fiber, vegetables, and fruit were found to be protective. Individuals with moderate and high salt intake had a 1.41 and 1.68 relative risk (RR) for GC, respectively, compared with those who consumed low levels of salt. Additionally, in the presence of H pylori infection, high salt intake further increases the risk of GC. Significant associations were found between the consumption of processed meat (RR 1.45 95%, CI 1.26-1.65) and GC risk. This association between processed meats and GC been described to be stronger in subjects infected with H pylori. Although obesity has not been found to be associated to all GCs, several meta-analyses have reported a positive association between increased body mass index (BMI) and risk of GC in the cardia.

Eradication of Helicobacter pylori for Gastric Cancer Prevention

H. Pylori eradication has been one of the major therapeutic strategies to reduce gastric cancer incidence in healthy individuals and gastric cancer patients who have undergone endoscopic mucosal resection. The number of gastric cancers diagnosed and treated at an early stage increased after the development of endoscopic treatments. Ten years ago, more than 50% of early-stage gastric cancers were endoscopically treated, and the 5-year survival rate of early-stage gastric cancer patients after endoscopic treatment was 90% [4]. Large lesions can be resected en block, including both the mucosa and sub mucosa by endoscopic sub mucosal resection (ESD), which has improved histopathological diagnosis and decreased tumor recurrence. The endoscopic removal of early-stage gastric tumors does not affect the overall cancer risk. Research on gastric cancers after H. Pylori eradication has been conducted for more than a decade. In 2008, an open-label, randomized controlled trial indicated that the occurrence of meta chronous gastric cancer is reduced by approximately 1/3 after eradication [5]. This study led to the recommendation of H. Pylori eradication in patients with endoscopically treated gastric cancer. In Japan in 2013, health insurance covered H. Pylori eradication as a treatment for gastritis, and this treatment was expected to reduce the incidence of gastric cancer [5]. However, a subsequent Japanese study indicated that even after H. Pylori infection is cured and gastric inflammation is eliminated, the risk for developing gastric cancer remains; furthermore, this risk was dependent on the level of gastric mucosal atrophy present before eradication therapy [6]. Thus, the gastric mucosa endures continuous H. Pylori-induced inflammation that increases the risk of metachronous gastric cancer even after treatment. Previous studies revealed that H. Pylori eradication does not reduce the incidence of metachronous gastric cancer in patients who underwent endoscopic resection and recommended that eradication should be performed before the progression of gastric mucosal atrophy. Extensive atrophy in the stomach and intestinal metaplasia of multiple areas causes gastric cancer and may increase the risk for metachronous gastric cancer when compared with cases of chronic gastritis mucosal [7-10].
Currently, the success of a gastric cancer prevention strategy depends on timing because the treatment must be introduced before the progression of gastric carcinogenesis. However, recent studies on gastric cancer suppression suggested that critical features of gastric carcinogenesis can be reversed via molecular mechanisms.
Thus, monitoring patients for signs of gastric cancer after eradication is important. Here, we review the observed macroscopic and histological gastric mucosal changes, risks for metachronous gastric cancer, and possible approaches for reducing gastric cancer. We also discuss some of the potential molecular mechanisms for gastric cancer development after eradication.
Meta-analysis shows that H pylori eradication is associated with a reduction of gastric cancer risk even among high-risk individuals, supporting that H pylori eradication is beneficial in individuals with atrophic gastritis and/or intestinal metaplasia. Other lines of evidence also support our finding. First, almost all gastric cancer patients have atrophic gastritis and/or intestinal metaplasia, [11] and our meta-analysis showed that eradicating H pylori after endoscopic resection of early gastric cancer reduced the risk of metachronous cancer by 54%. Second, our population-based mass eradication program on Matsu Island of Taiwan found that H pylori eradication could reduce the severity or reverse the presence of atrophic gastritis among subjects with premalignant gastric lesions at baseline and reduced gastric cancer incidence by 25% from 40.3 to 30.4 per 100,000 person years.
A meta-analysis published this month in the journal Gastroenterology [1] found that treatment of the bacterium Helicobacter pylori (H pylori) with antibiotics in a population at high risk for stomach cancer is associated with a reduced incidence rate of stomach cancer [4].
The reduction was statistically significant when researchers looked at the effect in high-risk populations (P=.037), or older patients (P=.023). After adjustment for baseline risk, eradication of H pylori was associated with a risk reduction of stomach cancer amounting to approximately 50%, according to lead author Yi- Chia Lee [4] attending physician and clinical associate professor at National Taiwan University Hospital in Taipei.
Researchers concluded that past meta-analyses, which found no statistically significant benefit [2], were flawed because they did not take into account the extended follow-up time required to determine the results in a population with less risk for stomach cancer. The topic has been controversial, as the possibility of eradicating H pylori has been intensely studied as a possible strategy for reducing stomach cancer since 2005, when Barry Marshall and Robin Warren received the Nobel Prize for discovering the role of the pathogen in gastritis and peptic ulcer disease.
The bacterium is thought to cause stomach cancer by first giving rise to chronic inflammation of the gut, which develops into multifocal atrophic gastritis (MAG), and eventually intestinal metaplasia in which the tissue of the stomach resembles colon tissue, leading to frank adenocarcinomas. For this reason, H Pylori, which infects half the world’s population, is thought to be a major global public health threat.
In the study, Lee et al. [3] performed a review of scientific literature through May 2015 of studies that examined the effect of eradication, using sources such as PubMed, the Cochrane Library, ClinicalTrials.gov, and Digestive Disease Week abstracts. Researchers compiled data on 48,064 individuals with 715 cases of gastric cancer from the studies and abstracts, the article said. Of the studies, 14 were conducted in asymptomatic individuals with H pylori, while 10 studies were done in patients who had undergone endoscopic resection of early gastric cancers. Looking at the data set as a whole, there was no statistically significant difference in prevalence between those who underwent eradication therapy compared with those who did not (P=.67). But the baseline rate of gastric incidence varied widely between studies, ranging from 34.3 to 10,256.4 per 100,000 person-years, the article said. But when the researchers looked only at those populations with intermediate or highest tertiles of risk, the reduction in gastric cancer following H pylori eradication was statistically significant.

Helicobacter pylori eradication

Because only a very small proportion of H Pylori-infected subjects develop GC, the benefit of mass H pylori eradication campaigns to prevent GC remains unsubstantiated. However, treatment and eradication of H Pylori infection is recommended in patients with gastritis. H pylori eradication has been reported to restore gastric histology to normal in individuals with chronic gastritis and atrophic gastritis without IM. Atrophic gastritis has been reported to undergo regression within 1 or 2 years after successful eradication of H pylori. The presence of IM in H pylori-associated chronic gastritis suggests a less reversible stage compared with atrophic gastritis alone. Evidence suggests that eradication at the IM stage is less effective and that lesions are more likely to progress. In a randomized 6-years follow-up clinical trial examining the role of anti-H pylori treatment and dietary antioxidant micronutrient supplementation in reducing the progression of precancerous lesions, use of anit-H pylori treatment or antioxidants was associated with significant inhibition of precancerous lesions including IM. This reversion of gastric atrophy and IM was confirmed after 12 years. The eradication of H pylori in GC patients with prior endoscopic resection reduces the incidence of new tumors and the extent of 1m. There are controversial data regarding the effect of H pylori eradication on the development of gastric epithelial dysplasia. At present, prophylactic H pylori eradication is strongly recommended after endoscopic tumor resection in EGC to prevent recurrence of malignancy.

Signs and Symptoms

Early gastric cancer has no associated symptoms; however, some patients with incidental complaints are diagnosed with early gastric cancer. Most symptoms of gastric cancer reflect advanced disease. All physical signs in gastric cancer are late events. By the time they develop, the disease is almost invariably too far advanced for curative procedures.

Signs and symptoms of gastric cancer include the following:

i. Indigestion
ii. Nausea or vomiting
iii. Dysphagia
iv. Postprandial fullness
v. Loss of appetite
vi. Melena or pallor from anemia
vii. Hematemesis
iii. Weight loss
ix. Palpable enlarged stomach with succession splash
x. Enlarged lymph nodes such as Virchow nodes (i.e. left supraclavicular) and Irish node (anterior axillary)

Late complications of gastric cancer may include the following features:

1. Pathologic peritoneal and pleural effusions
2. Obstruction of the gastric outlet, gastro esophageal junction, or small bowel
3. Bleeding in the stomach from esophageal varices or at the anastomosis after surgery
4. Intrahepatic jaundice caused by hepatomegaly
5. Extra hepatic jaundice
6. Inanition from starvation or cachexia of tumor origin

Diagnosis

Testing

The goal of obtaining laboratory studies is to assist in determining optimal therapy. Potentially useful tests in patients with suspected gastric cancer include the following:
a) CBC: May be helpful to identify anemia, which may be caused by bleeding, liver dysfunction, or poor nutrition; approximately 30% of patients have anemia
b) Electrolyte panels
c) Liver function tests
d) Tumor markers such as CEA and CA 19-9: Elevated CEA in 45-50% of cases; elevated CA 19-9 in about 20% of cases
e) Imaging studies
f) Imaging studies that aid in the diagnosis of gastric cancer in patients in whom the disease is suggested clinically include the following:
i. Esophagogastroduodenoscopy (EGD): To evaluate gastric wall and lymph node involvement
ii. Double-contrast upper GI series and barium swallows: May be helpful in delineating the extent of disease when obstructive symptoms are present or when bulky proximal tumors prevent passage of the endoscope to examine the stomach distal to an obstruction
iii. Chest radiography: To evaluate for metastatic lesions
iv. CT scanning or MRI of the chest, abdomen, and pelvis: To assess the local disease process and evaluate potential areas of spread
v. Endoscopic ultrasonography (EUS): Staging tool for more precise preoperative assessment of the tumor stage

Biopsy

Biopsy of any ulcerated lesion should include at least six specimens taken from around the lesion because of variable malignant transformation. In selected cases, endoscopic ultrasonography may be helpful in assessing depth of penetration of the tumor or involvement of adjacent structures.
Histologically, the frequency of different gastric malignancies is as follows [3]:
a) Adenocarcinoma - 90-95%
b) Lymphomas - 1-5%
c) Gastrointestinal stromal tumors (formerly classified as either leiomyomas or leiomyosarcomas) -2%
d) Carcinoids -1%
e) Adenoacanthomas -1%
f) Squamous cell carcinomas -1%

Management

Guidelines in Europe and the US have been proposed for management of GC depending on location, stage, and surgical candidacy. GC screening in countries with high-risk populations is effective in identifying EGC, which can be treated endoscopically. Accurate pretreatment staging is critical in identifying EGC patients with disease that is limited to the mucosa and sub mucosa (stage T1) and who are candidates for endoscopic mucosal resection of most lesions and is the preferred technique (ESD). ESD permits en bloc resection of most lesions and is the preferred technique for resecting EGC in Asia, with a complete en bloc resection rate of 87.7% and low complication rates. ESD has been reported to outperform EMR for en bloc, complete, and curative resection with lower recurrence rate. In the US, ESD is rarely performed outside referral centers with expertise in this technique. Depending on the size and location of the primary tumor, the preferred means of therapy is surgical resection with total or subtotal gastrectomy. Early Gastric cancer (EGC) is defined as a cancer confined to the mucosa and sub mucosa independently of the nodal status. The incidence of EGC in countries where there is mass screening for gastric cancer is around 53% and 5-year survival rates are above 90% in welldifferentiated, mucosal lesions without nodal involvement [12]. Patients with a family history of non hereditary gastric cancer have a higher risk of developing gastric cancer. E-cadher in mutations occur in approximately 25% of families with the autosomal dominant form of hereditary diffuse gastric cancer (HDGC)
EGC is defined as tumors confined to the mucosa or sub mucosa independently of the nodal status.
EMR and ESD are comparable techniques to radical surgery in the treatment of EGC that met the strict criteria for endoscopic treatments based on large Level II-3 data source. There no randomized trials comparing EMR and gastrectomy. Radical surgery with limited lymphadenectomy (Modified) gastrectomy type A (MGA) or type B [MGB] for EGC that do not meet the criteria for endoscopic procedures should be offered as the standard of care. Gastrectomy type A [MGA] or type B [MGB] for EGC that do not meet the criteria for endoscopic procedures should be offered as the standard of care.

Treatment of Advance Gastric Cancer

The primary goal of this therapy is to improve progressionfree survival (PFS) and overall survival (OS). The MAGIC trial used preoperative and postoperative epirubicin, cisplatin and 5-fluorouracil (ECF) combination chemotherapy. The role of neo adjuvant chemo radiation therapy in patients with potentially respectable esophageal and cardiac adenocarcinomas was supported in a sentinel study by Walsh et al. [13]. The extent of gastric tomy and lymphadenectomy should be tailored according to the stage of the tumor. A subtotal gastric tomy should be sufficient provided that an RO resection can be achieved. An MGA or MGB is recommended for EGC. For advanced gastric cancers expert opinion would favor radical gastric tomy with a D2 lymphadenectomy, but the best evidence currently supports gastric tomy with D1 lymphadenectomy in western patients. Extended lymphadenectomy (D3-D4) and routine pancreatictomy and/or spleenectomy are not supported by the data. A minimum of 15 lymph nodes should be harvested for adequate staging of advanced gastric cancers. There is insufficient data to recommended adjuvant therapy for node negative T1 and T2 gastric cancers. In node positive and advanced gastric cancers, adjuvant chemo radiation therapy should be offered due to the high loco regional and systemic recurrence rate. And acceptable minimal alternative after adequate R0 resection of advanced gastric cancers would be 5-fluorouracial or S-1 based chemotherapy. The high incidence of recurrence after R0 resection of advanced gastric cancer makes it imperative to recommend adjuvant therapy to optimize survival probability. Stage IV gastric patients should be offered chemotherapy as first-line therapy to prolong survival and palliation of symptoms. In highly selected group of patients, with good performance status surgery can be considered. In the presence of gastric outlet obstruction, GJJ should be offered in patients with a life expectancy of 2 months or longer.
Although several targeted therapies have been studied, only 2 targeted GC treatments have been approved for use in the US. Inhibition of human growth factor receptor 2 (HER2) has been tested as a targeted therapy for several cancers, including GC, Trastuzumab is a monoclonal antibody that targets HER2- dependent tumors. The trastuzumab for gastric cancer (ToGA) trial, a phase III international study evaluating the efficacy of trastuzumab in combination with conventional therapy (cisplatin plus 5-fluorouracil or capecitabine), showed improvement in the overall survival compared with chemotherapy alone. Ramucirumab, a human monoclonal antibody against the vascular endothelial growth factor receptor 2 (an important signaling pathway in GC and gastroesophageal cancer), is the first biologic therapy approved by the US Food and Drug Administration used as a single agent that demonstrates survival benefit in patients with advanced GC or gastroesophageal cancer who have progressed after first-line treatment.

National Comprehensive Cancer Network (NCCN) guidelines for treatment of early-stage (Tis, or T1) gastric cancer are as follows [4]:

a. Endoscopic mucosal resection or surgery are the standard treatment options
b. Complete surgical resection offers the potential for longterm survival
c. No further treatment is necessary if there is no residual disease

The NCCN guidelines for treatment of stage IB to IIIC gastric cancer are as follows [4]:

a) For medically fit patients with potentially resettable tumors, preoperative chemotherapy (category 1 recommendation) or chemo radiotherapy followed by surgery is appropriate
b) Postoperative chemo radiation or chemotherapy is indicated for patients who have undergone primary D2 lymph node dissection
c) For patients with unresettable tumors, treatment with fluoropyrimidine or taxane-based chemo radiotherapy (category 1 recommendation) or chemotherapy is acceptable.

The European Society for Medical Oncology/ European Society of Surgical Oncology/ European Society for Therapeutic Radiology and Oncology (ESMO-ESSOESTRO) follows:

1) Multidisciplinary treatment planning is mandatory; the management team should include surgeons, medical and radiation oncologists, gastroenterologists, radiologists, and pathologists plus, if available, dieticians and nurse specialists
2) T1a gastric cancers may be amenable to endoscopic resection if they are well-differentiated, ≤2cm, confined to the mucosa, and not ulcerated
3) With T1 tumors that do not meet the criteria for endoscopic therapy, lymph node dissection during open surgery can be limited to peri gastric nodes and include local N2 nodes
4) The preferred treatment for operable gastric cancers beyond stage T1N0 is surgery with both preoperative and postoperative chemotherapy
5) For patients with stage IB disease or higher who do not receive preoperative chemotherapy, the treatment options include either chemo radiotherapy or chemotherapy in the adjuvant setting.
6) Radical gastrictomy is indicated for resettable stage IB– III disease, although subtotal gastrectomy may be performed if a macroscopic proximal margin of 5cm can be achieved between the tumor and the esophagogastric junction (8cm for diffusetype cancers)
7) For medically fit patients, D2 lymph node dissection should be standard
8) For inoperable or metastatic gastric cancer, treatment is with palliative chemotherapy, or best supportive care if the patient is unfit for treatment
9) In HER-2 negative disease, combination regimens based upon a platinum–fluoropyrimidine doublet are generally used; triplet regimens are controversial, but the addition of an anthracycline (e.g. epirubicin) has demonstrated benefit
10) In HER-2 positive disease, recommended chemotherapy is with trastuzumab plus c is platin and either 5-fluorouracil or capecitabine
11) Second-line chemotherapy options include irinotecan and docetaxel or paclitaxel

Palliative Surgical Treatment

The best palliation in GC whenever possible is still surgical resection. In fact, morbidity and mortality of palliative surgery without resection (laparotomy alone or by-pass procedures) is extremely high and should be avoided. Perhaps a better preoperative evaluation by CT scan (heliscan) and/or laparoscopic staging indicated in selected patients could decrease the number of explanatory laparotomy in unresettable GC. Although, 25% of the patients with diagnosed GC can benefit from palliative procedures [3]. There are two different types of the palliative treatment of GC: resection of the tumor and surgical by-pass procedures without resection. Actual pre-operative investigations can not always predict the type of operative procedure as exactly as during operative exploration. Laparoscopic staging could be indicated in these conditions. Mostly, in many cases, the possibility of tumoral resection appears to surgeons as a perioperative finding, and per-operative manual exploration may find hepatic metastasis, wide or localized peritoneal implants. In these conditions, palliative surgery depends on local anatomy and preoperative clinical symptoms. A bleeding tumor is more to be resected than an obstructive one for which a by-pass might be recommended. In a general manner, oncologic rules of resections must respect the followings: little free margin on surrounding organs, inutility of lymph node dissections, unless it is required to obtain a free margin. There is a lower mortality and morbidity in palliative resections rather than in by-pass without resections. However, by-pass procedures can still be indicated when resection risk appears to be too high (morbidity and mortality) and/or in case of biliary and/or digestive obstruction. Then, a gastroenterostomy and/or a biliary diversion may be realized.

Non Operative Treatment

Non surgical treatment represents 30% of diagnosed GC [3] and is indicated in case of diffuse hepatic, peritoneal and/ or extra-abdominal metastasis without obstructive symptoms, sub-clavicular lymph nodes and/or the presence of severe physiological disorders and/or undernutrition. Treatment in these cases is difficult and varies from abstention to endoscopic des obstruction (endoscopic laser therapy, argon beam, heater probe coagulation therapy, endoscopic stent). Chemotherapy can be indicated only in phase II protocols.

Progress in Treatment of Advanced Gastric Cancer

Cancer immune therapy agents have gained great attention over the past several years for their exciting results across various types of cancer. Immunotherapies have been tested in melanoma, breast, prostate, kidney, and lung cancers, and are now being studied in advanced gastric cancers. Two monoclonal antibody agents, pembrolizumab (Keytruda) and nivolumab (Opdivo) have already shown promising results for their antitumor activity in PD-L1-positive advanced and metastatic gastric and gastro esophageal junction cancers [10].

Pembrolizumab

Pembrolizumab is an anti-PD-1 antibody tested in the treatment of several types of advanced cancer. The FDA has approved the use of pembrolizumab for the treatment of metastatic melanoma and advanced non–small cell lung cancer, and it has provided the drug with breakthrough status for relapsed or refractory classical Hodgkin lymphoma.
Pembrolizumab was studied in the treatment of PD-L1- positive recurrent or metastatic adenocarcinoma of the stomach or gastroesophageal junction in the phase Ib Keynote-012 study. Findings from the study were presented at the 2015 ASCO Annual Meeting.
The study was completed across 13 cancer research centers in the United States, Israel, Japan, South Korea, and Taiwan, to compare the results of patients from the Asian Pacific-where gastric cancers are more common-to patients from the rest of the world.
Archival tumor samples from 162 patients were screened for PD-L1 expression using a prototype immune histochemistry assay with the 22C3 antibody. Sixty-five patients (40%) were found to be eligible, of which 39 patients enrolled in the study and 36 of 39 were evaluable for assessment.
At baseline, there were 19 Asian patients and 20 patients from elsewhere in the world. Of these, the primary tumor site for the 19 patients from Asia was the stomach compared with 9 of the patients from the rest of the world. The gastro esophageal junction was the primary site for the remaining patients (n=11). At least 2 prior therapies for advanced disease were received by 67% of all patients.
Patients were given pembrolizumab intravenously at 10mg/ kg every 2 weeks for up to 24 months with responses tested every 8 weeks. As of the 12-month mark, 42% of the patients were still alive. Objective response rate (ORR) was 22% (95% CI, 10%-39%) according to central review and 33% (95% CI, 19%-50%) by investigator review. Partial response (PR) was experienced by 8 patients and 5 patients had stable disease (SD). No complete responses were observed.
Thirty-three patients (85%) discontinued treatment on pembrolizumab, 32 due to progressive disease and 1 due to an unrelated adverse event (AE). According to the investigator review, 26 patients (67%) had at least 1 treatment-related AE, including mostly grade 1/2 fatigue (13%), decreased appetite (13%), pruritus (13%), hypothyroidism (10%), and arthralgia (10%). Five patients (13%) experienced grade 3/4 AEs including 2 cases of grade 3 fatigue, grade 3 pemphigoid, grade 3 peripheral sensory neuropathy, grade 3 hypothyroidism, and 1 grade 4 pneumonitis. Four patients (10%) temporarily stopped treatment due to immune-mediated toxic effects and 2 of these patients were unable to continue, 1 due to progressive disease. One treatment-related death was noted in the abstract for the 2015 ASCO Annual Meeting but not in the final report.
Pembrolizumab is also being tested in additional clinical trials for gastric cancer treatment, including one phase III trial of pembrolizumab versus paclitaxel for treatment of progressive disease after previous platinum and fluoro pyrimidine-based chemotherapy treatment.

Nivolumab

Nivolumab is a fully human immunoglobulin G4 monoclonal antibody that has already received FDA approval for the treatment of advanced renal cell carcinoma, non-small cell lung cancer, Hodgkin lymphoma, and unresectable or metastatic melanoma. The therapy has also received a breakthrough therapy designation for recurrent or metastatic squamous cell carcinoma of the head and neck. In the phase I/II CheckMate-032 study patients with advanced or metastatic gastric or gastroesophageal junction cancer were treated with nivolumab or nivolumab plus ipilimumab. A majority of the patients (83%) had already received 2 or more prior treatments for gastric cancers. Patients were enrolled into the study regardless of their PD-L1 expression but responses were tested for both PD-L1-positive and -negative tumors. According to findings to be presented at the 2016 Gastrointestinal Cancers Symposium, single-agent nivolumab was well tolerated by pretreated patients. ORR was 12% with 1 complete response and 6 partial responses out of 58 patients, and 12 patients (21%) had stable disease. The median duration of response among responders was 7.1 months (95% CI, 3.0-13.2). The median overall survival duration was 6.8 months (95% CI, 3.3-12.4), with a 1-year survival rate of 38% (95% CI, 23.2-52.7). Patients with PD-L1-positive (39%) and -negative (61%) tumors had ORRs of 18% and 12%, respectively. At the time of the analysis, 10 patients were still on active treatment and 49 had discontinued, 40 due to progressive disease, 4 from unrelated AEs, and 2 from treatment-related AEs. Overall, treatmentrelated AEs occurred in 66% of patients, mostly low-grade, yet 14% experienced grade 3/4 AEs including pneumonitis, fatigue, diarrhea, vomiting, hypothyroidism, and increased aspartate, alanine aminotransferase, and alkaline phosphatase levels. No treatment-related deaths occurred. Findings are yet to be released for the patients that were treated with both nivolumab and ipilimumab. The nivolumab/ ipilimumab combination is FDA-approved for advanced metastatic melanoma.
Further clinical trials for the treatment of gastric cancer are ongoing. While these are just the first steps in immunotherapy research for gastric cancer, further research could result in increased survival rates for patients with advanced gastric cancers. Although substantial improvements in the management of gastric cancer have been made over the past several decades, overall out comes remain disappointing with unsatisfactory cure rates in all but the earliest-stage patients. The optimal treatment paradigm for most patients with gastric cancer remains unclear and may vary with tumor histology and location. Furthermore, it appears that the traditional pillars of oncology are approaching their limits, and that future innovations are sorely needed. Targeted agents, novel radio sensitizers, and even new modalities may be necessary to improve upon the successes of the past half-century. However, radiotherapy continues to play a crucial role for many patients, particularly those who did preoperative therapy, are found to have positive lymph nodes, retain residual disease following surgery, or are unresettable at diagnosis. The role of a trimodality approach in the neoadjuvant setting is promising, but its use is still investigational [14-21].


To Know More About Journal of Tumor Medicine & Prevention Please Click on: https://juniperpublishers.com/jtmp/index.php

To Know More About Open Access Journals Publishers Please Click on: Juniper Publishers

Wednesday, September 4, 2019

Assessment of Adult Patient Satisfaction and Associated Factors with Nursing Care Among Admitted Patient in Medical, Surgical, Obstetrics and Gynecology Ward in Mizan-Aman General Hospital, Bonga and Tepi Hospitals, Southwest Ethiopia 2016_Juniper Publishers

JOJ Nursing &Health Care Juniper Publishers




Authored by Sisay Shewasinad*

Abstract

Patient satisfaction could be a result of each patient’s perception of the care designed for that patient to eliminate his/her problems. Patient satisfaction, in most countries, is considered to be an indicator of the quality of healthcare and an important component of the care. The aim of this study is to assess adult patient satisfaction and associated factors with nursing care among admitted patient in medical, surgical and obstetrics and gynecology ward. The study was utilized an institutional based cross-sectional study design that employed both quantitative and qualitative data collection methods. Study participants were selected by random sampling technique. The data was collected through face to face interview using structured questionnaires. Both bivariate and multivariate logistic regression analysis was done. Overall proportion of adult inpatient satisfaction among the respondents was 184 (61.3%) and 116(38.7%) were dissatisfied with the nursing health care service provided at the inpatient. concluded that, adult inpatient satisfaction related to the health care services provided by the nurses is inadequate.
Keywords:Patient; Satisfaction; Nursing care

Introduction

Despite the availability of a wide range of quantitative and qualitative studies on patient satisfaction, there appears to be a lack of consensus on this issue from different investigators. Recognizing that patient satisfaction has something to do with how nursing care is received and appreciated, this study will look to find out exactly what nursing care factors contribute to patient satisfaction in hospitals. The problem is that, for the most part, it is not known what matters affect patients’ satisfaction with nursing care. Why is it that some patients are satisfied with nursing care while others are not? There is a need to find out this from the patients’ perspectives, as well as their hospital experiences, views and needs. This lack of a consensus on what constitutes patient satisfaction with nursing care poses a major challenge for the health services. Key performance indicators are used to monitor and evaluate the effectiveness and efficiencies of organizations and their staff. Patient satisfaction is one of the essential indicators for healthcare service improvement. From that view, the patient satisfaction survey is an instrument in monitoring health care delivery of a hospital in relation to nursing care. Specifically, inpatient department is the first-line healthcare service provided to patients [1]. Therefore, the quality of care will indicate the quality of service of the hospital as perceived by the patients regarding various factors. this study also initiates further research in the area.

Objective

General Objective: To assess adult patient satisfaction and associated factors with nursing care among admitted patient in medical, surgical and obstetrics and gynecology ward of MAGH, Bonga and Tepi Hospitals, 2016.
Specific Objectives: To determine the satisfaction levels of admitted adult patient in medical, surgical and obstetrics and gynecology wards in selected hospitals, 2016
To assess determinant factor affecting admitted adult patient satisfaction in medical, surgical and obstetrics and gynecology wards in selected hospitals, 2016 [2,3].

Methodology

Study Area and Study Period

The study was conducted in selected health institutions MTUTH, Bonga and Tepi hospitals southwestern Ethiopia from February 1st to May last.

Study Design

The study was utilized an institutional based cross-sectional study design that employed both quantitative and qualitative data collection methods to assess adult patient satisfaction and associated factors with nursing care among admitted patient in selected hospitals [4-6].

Source Population

The source population were all admitted adult patients in medical, surgical and obstetrics and gynecology ward of MTUTH, Bonga and Tepi hospitals who have at least two days admission [7].

Study Population

Study population were sampled admitted adult patient in selected health institution in medical, surgical and obstetrics and gynecology ward of MTUTH, Bonga and Tepi hospitals who have at least two days admission [8-10].

Eligibility Criteria

Inclusion Criteria: All admitted adult patients whose age is greater than 18 years and who have at least two days admission in medical, surgical and obstetrics and gynecology ward from selected health institution during the study period [11].
Exclusion Criteria: Admitted adult patients who were unable to participate due to mental illness and other causes were excluded.

Sample Size Determination

The sample size was determined by using single population proportion formula. The following assumptions were made, marginal error (W) that will be tolerated in either sides of the true proportion to be 5%, and using 95% confidence level and adding 10% to compensate for non responses and the proportion of patient satisfaction with nursing care (P), 77% from research done at Jimma University Specialized Hospital [12-14].
By assuming non-response rate 10%, the total sample size will be:
Sample size = (272 x10%) + 272 = 300

Antifungal resistance

For qualitative part: participants were selected purposely from chronically admitted patients. The samples were considered as sufficient, when the information we got will get saturated.

Sampling Technique

Quantitative Part: Study participants were selected by random sampling technique (non replaced lottery method). First the sample was determined depends up on the patient flow to each wards of the selected hospitals then the total number of sample size was proportionally allocated to each wards selected hospitals depending up on the patient flow [15,16].
Qualitative Part: Key informants like chronically admitted patient were selected using purposive sampling for in-depth interview. The sample was considered sufficient, when the information we got were got saturated [17].

Data Collection Technique and Tools

Data on patient satisfaction levels were collected through interview using standard questionnaire/ tool, the Newcastle Scale of Satisfaction with nursing /NSSN/, is a 19-item scale assessing patient satisfaction with nursing care service received in inpatient. The scale includes statements about aspects of the nursing care services provided at admitted patients which respondents are asked to rate them on a Likert scale ranging from 1 to 5, where one is “poor” and 5 is “excellent.” The scale is scored by summing each item. Higher scores indicate greater satisfaction with nursing care services, while lower scores indicate less satisfaction. Nine Bsc Nurses from health centers were involved in data collections who were speaker of Amharic and local language. The principal investigators were supervisors. For qualitative, the data collection was employed with in depth interview through probing questions. Tape recorder was employed to the area where in depth interview was conducted and note and observation also were undertaken. Chronically admitted patient (who will not be involved in quantitative survey) were involved [18-20].

Variables

Dependant Variable: Patient satisfaction
Independent Variables: Socio-Demographic characteristics: - age of the patient, sex of the patient, marital status, educational status, economic status (income), place of resident and occupation [21-23].

Data Quality Assurance

Interviewers were trained on methods of data collection. Questionnaires were checked on daily basis for completeness during data collection and were cleaned and coded before data entry. Data analysis was started by sorting and performing quality control checkup. Data was checked to ensure that all the information were properly collected and recorded. Before and during data processing the information was checked for completeness and internal consistency. The questionnaire was pre-tested before data collection, pre-testing was done in same health facility, but out of the selected wards. For qualitative part proper information was provided for every participant about the importance of the study which helps us to elicit more information from the interviewee [24].

Data Processing and Analysis

For quantitative data processing, master sheet or template was prepared and the data was entered, categorized, coded, and summarized using EPI 6 and transformed to SPSS version 20.00 in the computer for further analysis. Frequency and proportion were computed for description of study population in relation to socio demographic and other relevant variable (age, marital status). Both bivariate and multivariate logistic regression analysis were done to see the association of each categories of each variable with the outcome variable. Significances were checked at 95% CI in binary logistic regression. Variables with p<0.25 in binary logistic regression analysis were entered in multivariate logistic regression analysis to control for potential confounding variables [25-27].

Ethical Consideration

Permission letters were obtained from research and community service directorate of MTU. All the study participants were informed about the purpose of the study. Prior to data collection, verbal consent were obtained from the study participants. All information that was obtained from the individual was treated confidentially. Permission to audio-record for the interview was also obtained. Participants were not face any harm and were not receive any financial incentive for participating and it was solely on voluntary based [28].

Dissemination of Result

The result of the study will be communicated to relevant bodies including to MTU and the selected health sectors. Furthermore, all attempts will be made to present the findings to scientific conference and attempt will be made to publish the finding in reputable journal.

Result

Quantitative Findings

A total of 300 eligible patients were interviewed from MTUTH, Bonga Hospital and Tepi Hospital with 100% response rate [29].

Socio-Demographic Characteristics of the Respondents

Table 1 Socio-demographic characteristics of the respondents (n=300) in MTUTH, Bonga Hospital and Tepi Hospital, Bench Maji Zone, South West Ethiopia, June 2016. Overall quality of nursing care provided in inpatient ward with the respective to the patient satisfaction indicated that most of the inpatient about 53.3 % of them has replied that there is fairly satisfaction related to the overall quality of nursing care provided in the inpatient ward (Figure 1). Adult patient satisfaction in the three selected hospital showed that most of the respondents about 61.3% of the total indicated that they are dissatisfied and the rest of the respondents 38.7% of the respondents are satisfied (Figure 2) [30-34].

Determinant Factors Related to Socio Demographic Variables Associated with the Inpatients Satisfaction

Qualitative Findings. Quality of nursing health care services and factors which influence it. The majority of the interviewee reflected mixing of opinions with no clear determination of the quality of nursing health care services provided in the inpatient wards. One of the interviewee from the inpatient said, “As to me the quality of nursing health care services in this inpatient ward is not that much attractive. Because as you have seen here, there is no enough room for patients and patients are obliged to admit at the hospital corridor and nurses therefore are not interested or volunteer to bring bed linen and find out alternative solution even were not interested or motivated to understand our pain.” (A 52 years of old male inpatient from MTUTH, surgical ward) Key attributes of patient-satisfaction in nursing health care services Regarding to the key attributes of patient satisfaction related to the nursing health care services one of the interviewee from the inpatient has replied, “There are some problems in which I was not satisfied even though there is also good nursing health care services (Table 2). For instance, things which makes me dissatisfied includes that nurses in this inpatient ward are not that much cooperative because the way that they respond to our question is not attractive and even they didn’t come as quickly as possible when we call them for help (Table 3). There are some nurses who provide us different services by wearing the same personal protecting equipments like gloves and especially this makes me discomfort when they touch me and administer medication with the gloves which were previously used. Additionally, I have appreciated one main problem here in this ward which is there are some nurses who lacks confidence related to medication administration.” (A 47 years of old male inpatient from MTUTH, medical ward) [35-39].


Discussion

Patient satisfaction has become an important indicator to measure the quality of care rendered to the patients while in hospital. The finding of this study showed that the overall satisfaction level of the patients with the nursing care services at Mizan-Tepi university teaching hospital, Tepi and Bonga Hospitals was 116(38.7%). This finding is lower than a study conducted at Jimma University Specialized Hospital revealed that the overall satisfaction level of the clients with the services was 77.0 % [40] and other study conducted at a Mozambique Hospital, Amhara region and Tigray zonal hospitals revealed that the overall satisfaction level of the clients with the services was 55%, 50% and 43.60% respectively [41-43]. The possible explanation for the observed difference could be the difference in socio-demographic characteristics of participants and upgrading different nurses to the next level. Among a number of socio-demographic and patient related factors included in this study, only few were identified as significant predictors of the patients’ overall satisfaction with nursing care services in the multivariate analysis [45-52]. These include place of resident and monthly income were found to be statistically significant predictors of patients’ satisfaction. In this study respondents who lived in urban were almost two times more likely to be satisfied with the nursing care given in the inpatients than who were rural residence (AOR = 1.875, 95% CI = [1.100, 3.196]), and respondents whose household income was >=750 Ethiopian birr were less likely to be satisfied with the nursing care in the inpatients than who were <750 Ethiopia birr (AOR = .126, 95% CI = [.022, .730]) it was incongruent with study done at Addis Ababa Black Lion Hospital multivariate analysis result showed that female (95%CI, AOR:.36(0.14, 0.93)) were more satisfied than male patients. Age=>50 years (95%CI, AOR:3.78(1.35, 10.56)) were less likely to be satisfied than patients age < 50 years and other study showed that the length of stay as well as previous experiences during hospitalizations also influenced patient satisfaction The length of stay as well as previous experiences during hospitalizations also influenced patient satisfaction [53].

To Know More About JOJ Nursing & Health Care Please Click on: https://juniperpublishers.com/jojnhc/index.php

To Know More About Open Access Journals Publishers Please Click on: Juniper Publishers

Tuesday, September 3, 2019

The Case for Drug Testing in Pediatric and Adolescent Medicine: Revisiting Brer Rabbit and the Tar Baby_Juniper Publishers


Academic Journal of Pediatrics & Neonatology Juniper Publishers



Authored by Martin H. Bluth

Case Report


In the classic folk tale Brer Rabbit and the Tar Baby, the second title of the Uncle Remus collection of stories from the late 1800’s, Brer Fox devises a plan to trap Brer Rabbit [1]. The fox positions a doll made of tar and turpentine on the road to goad the rabbit who becomes increasingly agitated when he speaks to the tar baby with no response. Brer Rabbit considers the Tar Baby’s lack of response so rude that he, ironically, begins physically attacking the Tar Baby to elicit a response. The result is a rabbit stuck deeper in tar with each strike and now at the mercy of Brer Fox.
Drug testing often imposes a similar quagmire of frustration when the laboratory yields curious results for the management of an adult or child patient. Oftentimes such a result elicits the need to “do something” to effectively manage the patient which can include performing more lab or radiologic tests, soliciting specialist consultation or other reactive as well as proactive actions. These actions can be implemented as much for patient management as for protection of the physician and his/her practice. The pediatric or adolescent patient is further unique in that he/she is often seen as a triumvirate of mother, father and child. Such an interaction requires a different type of sensitivity in addition to knowledge of both state specific confidentiality laws and interviewing skills specific to this age group and the subject of drug use and drug testing in this population as part of the medical evaluation. It is often the default position of the parent to wince at the mention of asking his/her child to submit for non- invasive (oral swab, urine) drug testing. Many parents may find it incredulous to suggest such as it posits that their child may be engendering in illicit or inappropriate behavior of some sort. This gestalt is further delineated from adult medicine in that a positive drug test in a child may cast aspersions on their efficacy as a parent, making communication regarding this topic even more fraught with difficulty [2].
In addition to the parental perspective, there is also the positioning of the pediatric or adolescent patient. Schwartz and colleagues assessed the perspectives of parents and adolescents regarding the ability to perform involuntary testing for drugs of abuse [3]. They queried parents and adolescents separately on whether parents have the right to ask a teenager’s physician to order a urine test for drugs of abuse without their knowledge in the setting of falling grades, uncooperative attitude and/or major untruthfulness without consent. The majority of the parents (>80%) approved of non-consented drug testing by the physician whereas only about half (~54%) of the teenagers agreed with this approach. In contrast, more teenagers (>30%) stated that parents have no such rights compared with parents (~11%). Although the American Association of Pediatrics cautions against involuntary drug testing in a competent adolescent without his or her knowledge as well as maintaining their confidentiality by not sharing the results with their parents, there are situations (i.e. acute risk of harm to self or others) when the pediatrician is mandated to breach this confidentiality [4]. In general, maintaining trust and communication of the dyad (patient/parent as well as patient/physician) and triad (patient/parent/physician) towards fostering a long term relationship and appropriate clinical management remains the ideal but can be difficult at times.
Nonetheless, due to the present opioid epidemic the need for drug testing in the pediatric population has increased dramatically. The ease of access to prescribed as well as illicit drugs are ever increasing [5]. Part of this is due to the increased prescribing of narcotic analgesics over the past 10 years, many of which remain stored in an accessible medicine cabinet years after the prescription is filled. Part of this is also due to social media connectivity opportunities through chat groups, nonpharmaceutical grade privately produced by street chemist and the like offering unparalleled accessibility compared with pre internet drug trafficking.
Children and adolescents can intentionally access narcotics by visiting grandma’s medicine cabinet or night table as well as the school yard, neighborhood contacts or internet [6]. In addition, unintentional ingestion of other substances is also of concern. Many supplements, herbs and other natural remedies which may be provided by parents to children for good reason may be tainted with other agents such as benzodiazepines or amphetamines causing various clinical sequelae [7]. This may be further augmented by other medications prescribed to the child causing differential metabolism of parent / metabolite agents as a result of CYP enzyme inducer and inhibitor relationships as a result of the ingested drugs.
According to the CDC, children >12 years have a prevalence of illicit drug use of 10.1% and nonmedical use of a psychotherapeutic drugs of 2.4% over a given month’s span [8]. Age based analysis shows that illicit drug use is highest 16-17 year old age group (16.3%) compared with those who are younger (14-15 year – 7.2% and 12-13 year – 2.6%). Marijuana use has increased aggregately over the last decade by 34% (6.2% in 2002; 8.3% in 2015) with similar patterns among races with the greatest use in 16-17 year old children (~15%) compared with younger children (14-15 years ~5%; 12-13 years ~1%) with no major differences in gender [8].
Furthermore, although, select substance use including alcohol, cigarettes, marijuana, cocaine, inhalants, and MDMA (Ecstasy) have decreased over the past three decades among all races, age groups and genders, they are maintained with some variability; i.e. ~35% alcohol ingestion among 12th graders compared with ~10% of 8th graders [8]. Thus, drug use and abuse is ever present in the pediatric and adolescent population and to this end, clinical laboratory toxicology testing can provide objective ancillary support for effective patient management if employed in the proper context.
It is important to understand the limitations of laboratory drug testing as much as the advantages of drug detection. Differentiating between a drug “screen” and “confirmation” is critical. A screen often uses immunoassay (IA) technology where the detection antibody utilized recognizes a class of drugs (i.e. opiates) rather than individual drugs in that class (codeine, morphine, hydrocodone, etc). Confirmatory testing utilizes gas or liquid chromatography along with mass spectroscopy (GC/ MS or LC/MS, respectively) to identify a molecular fingerprint of each individual drug often referred to as a “mass to charge” ratio. Screening assays are often found in the doctor’s office and have a faster turnaround time to result than confirmatory testing therefore increasing its appeal and presence in the laboratory testing algorithm.
However, immunoassays can cross react with other molecules yielding a false positive. For example, over the counter cold medicines containing pseudoephedrine can ‘screen’ positive for amphetamine on immunoassay but ‘confirm’ negative by LC/ MS. Screening assays also often have a higher limit of detection compared with confirmatory testing. Thus, a sample which contains 89ng/mL of cocaine may ‘screen’ negative by IA if the lower limit of detection (LOD) is 200 ng/mL but ‘confirm’ positive by LC/MS with an LOD of 50 ng/mL. Furthermore, the time of drug ingestion, frequency of use and type of specimen (urine, oral swab, blood, hair) all have different relationships with the biodistribution of a given drug and can affect results [9]
In either technology, detection of an analyte also depends on the presence of internal controls to validate what is being detected. Certain laboratories will test for different drugs of abuse compared with other laboratories. Such differences in test menu offerings are often due to clinical clientele, economics, and implementation logic. In addition, the ever present new street drug may not yet be detectable when the testing methods to detect them are not validated and/or available. Such examples include the Gray Death and Zombie drugs where labs have to keep in step with the street chemists [10,11]. Furthermore, sometimes validation of a new assay presents a health hazard to the clinical laboratory. The recent wave of carfentanil deaths were only assayed by certain labs (i.e. medical examiners) since incorporating method validation of carfentanil, a drug 100x more potent that fentanylnormally used to tranquilize elephants and rhinoceros, put laboratory staff at risk during specimen processing by experiencing a microcosm of the drug’s effects when airborn.
Home detection kits pose additional issues since these types of tests are often employed by a concerned parent or school where any result is not tempered with understanding of testing methodologies, interfering factors, limitations, or the clinical picture surrounding the plausibility of drug abuse (i.e. signs and symptoms, psychosocial environment) and the like. It important to understand that general routine laboratory drug testing results are not legally binding towards expulsion, incarceration, or reprimand. Only accredited labs that adhere to Substance Abuse and Mental Health Services Administration (SAMHSA) guidelines which include chain of custody of the procured patient sample (i.e. forensic laboratories) can provide results that can be used in a legal context [12]. In addition, variation of which pediatric or adolescent population are considered at risk, and should therefore be tested, vary among different societies and institutions (i.e. student athletes vs musicians). In certain studies, there were no apparent differences in self-reported drug use compared with tested drug use in students [13] casting doubt regarding the benefit of general drug testing in schools, without a clear understanding of who to test, when to test, how to test, and what to do with test results.
Any laboratory test should only be performed if the results will affect management in some manner. Drug testing in children in particular should never to be overcast as a punitive measureand should only be performed if there is a system in place to address drug abuse [14]. Many communities lack appropriate counseling/ support/detox services to treat children and adolescents with substance abuse disorders. Thus, clinical laboratory toxicology testing serves to provide objective ancillary support to the pediatrician in conjunction with other objective and subjective findings during examination of the patient to aid in diagnosis and management. Drug testing on children and teenagers should only be considered in the context of an existing bona fide support infrastructure, where care and management of addiction can be implemented. Anything less would be hitting the tar baby yet again.


To Know More About Academic Journal of Pediatrics & Neonatology Please Click on:
https://juniperpublishers.com/ajpn/index.php

To Know More About Open Access Journals Publishers Please Click on: Juniper Publishers

Cytotoxicity, Antimicrobial and Antioxidant Activities of Apocarotenoid Rich Leaf Essential Oil of Maesobotrya Barteri Var. Barteri (Baill.) Hutch - Juniper Publishers

  Technical & Scientific Research - Juniper Publishers Abstract Background: Maesobotrya barteri var. barteri (Phyllanthaceae) has anal...